Cancer Cachexia Market Size & Share, by Drugs (Progestogens, Dronabinol, Mega Sterol Acetate, Corticosteroids); Mode of Action (Weight Loss Stabilizers, Appetite Stimulants); Indication (Cancer, CHF, Rheumatoid Arthritis, Chronic Kidney Disease, Cystic Fibrosis, COPD); Route Of Administration (Oral, Parenteral); Dosage Form (Tablets, Injections); Distribution Channel (Hospital, Retail & Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• The Incidence of Chronic Illnesses is Rising- The market for cancer cachexia is expected to rise as chronic diseases including diabetes, cancer, heart failure, and others become more common. Heart failure (HF) affects about 6.7 million adults over the age of 20, and by 2030, that number is predicted to increase to 8.5 million. The lifetime risk of heart failure has risen to 24%; almost 1 in 4 people will get heart failure at some point in their lives. The market for cancer cachexia will grow as a result of the increased prevalence of cancer cachexia and the development of cutting-edge therapeutics to address it.
• Infrastructure Spending in the Healthcare Sector is Increasing- The market for cancer cachexia is also growing at a large rate due to increased healthcare spending, which supports the development of the industry's infrastructure. Additionally, by boosting funding, a number of government organizations hope to strengthen the healthcare infrastructure, which would further alter the dynamics of the market. The amount spent on Medicare increased by 8.4% to USD 900.8 billion in 2021, or 21% of the entire NHE. Medicaid spending increased to USD 734.0 billion in 2021, or 17.5% of the entire NHE, a 9.2% increase. In 2021, the amount spent on private health insurance increased by 5.8% to USD 1,211.4 billion, or 28% of the total NHE.
• Robust R&D and Pipeline for Products- Due to the high prevalence of cachexia instances among cancer patients worldwide, clinical research aimed at defining the features of cancer cachexia in a variety of human cancer types has received more attention. It is critical to comprehend the molecular pathways underlying muscle loss as cancer cachexia advances in order to enhance cancer outcomes. Furthermore, a surge in research and development efforts is driving the market's expansion. This will present advantageous prospects for the market expansion of cancer cachexia. In addition to these, an increase in drug launches and approvals will accelerate the market's growth rate.

Challenges

• Tight Regulating Guidelines- Since cancer cachexia is more common among cancer patients who are nearing the end of their lives, medications used to treat this condition typically have to closely follow the guidelines set by other medications used to treat cancer. Due to strict regulatory standards, several nations have lengthy approval processes for pharmaceuticals, particularly those connected to cancer. The amount of time needed for cancer medications to be approved by each country varies greatly depending on the current national regulatory norms. For instance, the FDA in the US is required to decide on standard applications within 12 months and on applications designated for priority review within 6 months.
• The high expense of the treatment will hinder the market's rate of growth.
• The market for cancer cachexia will face challenges due to the shortage of qualified practitioners in developing nations.